| Sep 16 |
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
|
| Sep 14 |
Ascendis Pharma A/S (ASND): Among Hedge Funds’ Top Biotech Stock Picks
|
| Sep 13 |
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
|
| Sep 11 |
Ascendis gets FDA orphan drug status for Yorvipath for hypothyroidism
|
| Sep 11 |
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
|
| Sep 5 |
Ascendis raised to outperform by Oppenheimer ahead of drug launch
|
| Sep 5 |
Ascendis Pharma Takes A Big Price Cut On Skytrofa
|
| Sep 4 |
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
|
| Sep 4 |
Why Ascendis Pharma Stock Tumbled by 11% Today
|
| Sep 4 |
Ascendis stock falls 12% amid lowered outlook, royalty deal
|
